Day: April 29, 2021

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage” or the “Company”) (CSE:ACRG.A.U, ACRG.B.U), (OTCQX: ACRHF, ACRDF) a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S., today announced Katrina Yolen has been appointed as the Company’s Chief Marketing Officer effective April 28th. “I am thrilled to welcome Katrina to the Acreage team and look forward to her significantly building brand awareness for our portfolio of brands,” said Peter Caldini, Chief Executive Officer of Acreage. “Katrina’s unique background, which combines traditional CPG brand management and cannabis, is exactly what Acreage needs to further expand its marketing and commercialization capabilities at the local, state, and national levels.” Katrina brings a wealth of marketing and brand management...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, will present interim data from the XLRP Phase 1/2 trial and Mark Pennesi, MD, PhD, will present interim data from the ACHM Phase 1/2 clinical trials. Details of XLRP Presentation: Session Title: Six-Month Findings from a Phase 1/2 Clinical Study of Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis...

– Toripalimab data will also be featured in ASCO’s official press program – SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021. The abstract has also been selected for ASCO’s official press program. Details regarding the plenary session and abstract publication are as follows:Title: JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as...

Coalition Expands Reach and Impact into the Business Community CANTON, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (OTCQX: “DXLG”), the leading omni-channel specialty retailer of Big + Tall men’s clothing and shoes, announced today that it joins the growing coalition pledging to advance diversity and inclusion in the workplace. One of nearly 2,000 CEOs that have come together for CEO Action for Diversity & Inclusion™, Harvey Kanter is committing himself and Destination XL Group, Inc. to this effort. By signing on to this commitment, Destination XL Group, Inc. is pledging to take action to cultivate a workplace where diverse perspectives and experiences are welcomed and respected, and where employees feel encouraged to discuss diversity and inclusion. The collective of nearly 2,000 signatories has already...

– Toripalimab data will also be featured in ASCO’s official press program – SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021. The abstract has also been selected for ASCO’s official press program. Details regarding the plenary session and abstract publication are as follows:Title: JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as...

Merger with Navios Maritime Containers L.P. completed on March 31, 2021 Revenue:$108.8 million total revenue for Q1 2021$65.1 million from Navios Partners $43.7 million from Navios ContainersNet cash from operating activities:$27.4 million total net cash from operating activities for Q1 2021$16.2 million from Navios Partners $11.2 million from Navios ContainersAdjusted EBITDA:$56.4 million total Adjusted EBITDA for Q1 2021$33.7 million from Navios Partners $22.7 million from Navios Containers$500.0 million financingRefinancing 2021 maturities No significant maturities until 2023Significant fleet expansion65% increase in number of vessels year-to-date$0.05 per unit cash distribution for Q1 2021MONACO, April 29, 2021 (GLOBE NEWSWIRE) — Navios Maritime Partners L.P. (“Navios...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, April 29, 2021 (GLOBE NEWSWIRE) — Appia Energy Corp. (CSE: API) (OTCQB: APAAF) (FSE: A0I.F) (FSE: A0I.MU) (FSE: A0I.BE) (the “Company” or “Appia”), is pleased to announce that it has entered into an agreement with Research Capital Corporation as sole underwriter and sole bookrunner (the “Underwriter”), whereby the Underwriter will purchase, on a bought-deal basis, securities of the Company (the “Securities”) for aggregate gross proceeds to the Company of $4,000,000 (the “Offering”). The Offering shall consist of a combination of: (i) units of the Company (each, a “Unit“) at a price of $0.60 per Unit; and (ii) flow-through units of the Company (each, a “FT Unit”) at a price of $0.70 per...

Industry veteran brings extensive management and operational experience to workers’ compensation industry leader IRVINE, Calif., April 29, 2021 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, has appointed Joseph Rupp as Area Vice President. Rupp brings to CorVel 30 years of experience, including a deep understanding of how to build a value-driven and disciplined sales and operations organization. As Area Vice President, Rupp will oversee the management and growth of people, revenue and profits in California. He will supervise product and employee performance, focus on meeting and exceeding market profit and revenue goals. He will also focus on growing market share and enhancing both process development and business solutions. “We are excited to welcome Joseph Rupp to the...